Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical Ltd announced the cessation of 18,942 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders, as it reflects on the company’s operational challenges in meeting set conditions for securities.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd operates in the medical industry, focusing on the development and commercialization of medical devices and treatments for cancer patients. The company is primarily known for its innovative solutions in oncology, aiming to improve the quality of life and treatment outcomes for patients with pancreatic and other types of cancer.
Average Trading Volume: 29,845
Technical Sentiment Signal: Sell
Current Market Cap: A$31.63M
For detailed information about OSL stock, go to TipRanks’ Stock Analysis page.